Publication of a Supplementary Prospectus

/**/

RNS Number : 3303M ANZ New Zealand (Int'l) Ltd 19 December 2025  

Publication of Supplementary Prospectus   The following supplementary prospectus has been approved by the Financial Conduct Authority and is available for viewing:   Supplement dated December 19, 2025, (the "Supplement") relating to the Base Prospectus dated November 20, 2025 for the U.S.$60,000,000,000 Euro Medium-Term Note Programme of ANZ Bank New Zealand Limited and ANZ New Zealand (Int'l) Limited.   To view the full document, please paste the following URL into the address bar of your browser:   http://www.rns-pdf.londonstockexchange.com/rns/3303M_1-2025-12-19.pdf   A copy of the Supplement has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.   For further information, please contact:   Steve Aquilina Treasurer ANZ New Zealand (Int'l) Limited Telephone: +44 20 3229 2013   DISCLAIMER - INTENDED ADDRESSEES   Please note that the information contained in the Supplement may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Supplement is not addressed.  Prior to relying on the information contained in the Supplement, you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of the information contained therein.   Your right to access this service is conditional upon complying with the above requirements.      

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  PSPEADANFESSFFA